CLYM ▲ +0.7% - Climb Bio, Inc. $CLYM - Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy Climb Bio shares rose 0.7% following the company's announcement of positive Phase 1 data for CLYM116, which showed a prolonged half-life and superior APRIL suppression that would support dosing only once every 12 weeks in IgA nephropathy patients. The extended dosing interval and potency profile represent potential advantages over competing therapies in development for the autoimmune kidney disease. 03-SEP-2026 07:00 AM ET